Drug Profile

Bortezomib - Takeda Oncology

Alternative Names: JNJ-26866138; LDP-341; MG-341; MLN-341; NSC-681239; PS 0341; PS-341; Velcade

Latest Information Update: 08 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Millennium Pharmaceuticals
Developer Bayer; Celgene Corporation; Childrens Mercy Hospital Kansas City; Dana-Farber Cancer Institute; Duke University; Erasmus MC; Genentech; Hoosier Cancer Research Network; HOVON Foundation; Indiana University; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; Millennium; Millennium Pharmaceuticals; Singapore General Hospital; Takeda Oncology; University of Michigan Comprehensive Cancer Center; Weill Cornell Medical College; Xian-Janssen
Class Amides; Anti-ischaemics; Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules; Vascular disorder therapies
Mechanism of Action Apoptosis stimulants; NF-kappa B inhibitors; Proteasome inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma; Mantle-cell lymphoma
New Molecular Entity Yes

Marketed Mantle-cell lymphoma; Multiple myeloma; Waldenstrom's macroglobulinaemia
Registered B-cell lymphoma
Phase III Diffuse large B cell lymphoma
Phase II Amyloid light-chain amyloidosis; Glioma; Graft-versus-host disease; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Phase I/II Acute myeloid leukaemia
Preregistration Submission Withdrawal Follicular lymphoma
No development reported Malignant melanoma; Neuroblastoma; Pancreatic cancer
Discontinued Adenocarcinoma; Cerebral ischaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Prostate cancer; Rheumatoid arthritis; T-cell prolymphocytic leukaemia

08 Mar 2024 Janssen Research and Development completes a phase III trial in Multiple myeloma (Combination therapy, First-line therapy) in China, Hong Kong, Taiwan, South Korea and Malaysia (SC, injection) (NCT03217812)
27 Feb 2024 Janssen completes the phase III LEPUS trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Taiwan and China (SC) (NCT03234972)
09 Dec 2023 Efficacy and adverse events data from a phase-III clinical trials in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition(ASH-Hem-2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com